[go: up one dir, main page]

SG11202006873UA - Combination therapy for treating or preventing cancer - Google Patents

Combination therapy for treating or preventing cancer

Info

Publication number
SG11202006873UA
SG11202006873UA SG11202006873UA SG11202006873UA SG11202006873UA SG 11202006873U A SG11202006873U A SG 11202006873UA SG 11202006873U A SG11202006873U A SG 11202006873UA SG 11202006873U A SG11202006873U A SG 11202006873UA SG 11202006873U A SG11202006873U A SG 11202006873UA
Authority
SG
Singapore
Prior art keywords
treating
combination therapy
preventing cancer
cancer
preventing
Prior art date
Application number
SG11202006873UA
Inventor
Alexander Stevenson
Original Assignee
4D Pharma Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1800927.4A external-priority patent/GB201800927D0/en
Priority claimed from GBGB1801502.4A external-priority patent/GB201801502D0/en
Priority claimed from GBGB1805941.0A external-priority patent/GB201805941D0/en
Priority claimed from GBGB1806572.2A external-priority patent/GB201806572D0/en
Priority claimed from GBGB1808631.4A external-priority patent/GB201808631D0/en
Application filed by 4D Pharma Res Ltd filed Critical 4D Pharma Res Ltd
Publication of SG11202006873UA publication Critical patent/SG11202006873UA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
SG11202006873UA 2018-01-19 2019-01-18 Combination therapy for treating or preventing cancer SG11202006873UA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB1800927.4A GB201800927D0 (en) 2018-01-19 2018-01-19 Combination therapy for treating or preventing cancer
GBGB1801502.4A GB201801502D0 (en) 2018-01-30 2018-01-30 Combination therapy for treating or preventing cancer
GBGB1805941.0A GB201805941D0 (en) 2018-04-10 2018-04-10 Combination therapy for treating or preventing cancer
GBGB1806572.2A GB201806572D0 (en) 2018-04-23 2018-04-23 Combination therapy for treating or preventing cancer
GBGB1808631.4A GB201808631D0 (en) 2018-05-25 2018-05-25 Combination therapy for treating or preventing cancer
PCT/GB2019/050143 WO2019141998A1 (en) 2018-01-19 2019-01-18 Combination therapy for treating or preventing cancer

Publications (1)

Publication Number Publication Date
SG11202006873UA true SG11202006873UA (en) 2020-08-28

Family

ID=65278398

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202006873UA SG11202006873UA (en) 2018-01-19 2019-01-18 Combination therapy for treating or preventing cancer

Country Status (14)

Country Link
US (2) US20210060086A1 (en)
EP (1) EP3740220A1 (en)
JP (1) JP2021516662A (en)
KR (1) KR20200110342A (en)
CN (1) CN111727047A (en)
AU (1) AU2019210004A1 (en)
BR (1) BR112020014565A2 (en)
CA (1) CA3088338A1 (en)
IL (1) IL276074A (en)
MA (1) MA51615A (en)
MX (1) MX2020007664A (en)
SG (1) SG11202006873UA (en)
TW (1) TW201934139A (en)
WO (1) WO2019141998A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114667159B (en) * 2019-11-04 2024-04-26 正大天晴药业集团股份有限公司 Pharmaceutical combination of quinoline derivative and PD-1 monoclonal antibody
WO2023072968A1 (en) * 2021-10-25 2023-05-04 4D Pharma Research Ltd Compositions comprising bacterial strains

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
EP2078042B1 (en) 2006-10-27 2019-06-12 Capsugel Belgium NV Hydroxypropyl methyl cellulose hard capsules and process of manufacture
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
RU2017141448A (en) * 2015-06-01 2019-07-15 Зэ Юниверсити Оф Чикаго TREATMENT OF CANCER BY MANIPULATION WITH COMMENSAL MICROFLORA
SG11201804161VA (en) * 2015-11-20 2018-06-28 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520497D0 (en) * 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41708A (en) * 2017-05-24 2020-04-08 4D Pharma Res Ltd COMPOSITIONS CONTAINING BACTERIAL STRAINS

Also Published As

Publication number Publication date
CA3088338A1 (en) 2019-07-25
MA51615A (en) 2020-11-25
WO2019141998A1 (en) 2019-07-25
EP3740220A1 (en) 2020-11-25
JP2021516662A (en) 2021-07-08
MX2020007664A (en) 2020-09-14
BR112020014565A2 (en) 2020-12-08
CN111727047A (en) 2020-09-29
US20210060086A1 (en) 2021-03-04
IL276074A (en) 2020-08-31
TW201934139A (en) 2019-09-01
KR20200110342A (en) 2020-09-23
AU2019210004A1 (en) 2020-08-13
US20230277602A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
IL290149A (en) Combination therapy for cancer treatment
IL267795A (en) Combination therapy for the treatment of cancer
EP3407978A4 (en) Combination therapy for treating cancer
GB201903546D0 (en) Cancer treatment
IL275949A (en) Combination therapy for treating or preventing cancer
IL282093A (en) Combination therapy for cancer
SG11202103141YA (en) Combination therapy for the treatment of cancer
IL287652A (en) Cancer treatment
IL284162A (en) Combination therapy for the treatment of cancer
IL266993A (en) Combination therapy for the treatment of cancer
IL281439A (en) Combination therapy for treating blood cancer
SG11202010528XA (en) Combinations for treating cancer
SG11202102492PA (en) Combination therapy for the treatment of prostate cancer
IL276073A (en) Combination therapy for treating or preventing cancer
IL276074A (en) Combination therapy for treating or preventing cancer
IL275860A (en) Combination therapy for treating or preventing cancer
IL288178A (en) Gmci and ddri combination therapy for treating cancer
IL286680A (en) Medicament for treating cancer
IL278921A (en) Combination therapies for treating cancer
GB201819920D0 (en) Cancer treatment
IL253642A0 (en) Combination therapy for the treatment of cancer
GB201808628D0 (en) Combination therapy for treating or preventing cancer
GB201808631D0 (en) Combination therapy for treating or preventing cancer
GB201808632D0 (en) Combination therapy for treating or preventing cancer
GB201808636D0 (en) Combination therapy for treating or preventing cancer